论文部分内容阅读
目的探讨mdr-1基因产物P-糖蛋白在胆管癌中的表达和对化疗的影啊方法应用SP免疫组织化学方法研究35例胆管癌,20例胆系良性病变组织多药耐基因(mdr-1)产物P-糖蛋(P-GP)的表达情况。结果 35例胆管癌P-GP阳性表达12例(34.3%),胆系良性病变2例(10%),两者差异有显著性意义;术后化疗再手术者P-GP,阳性表达率为83.3%(5/6)与化疗明显相关。P-GP的表达与胆管癌病理类型、 TNM分期不相关。结论胆管癌P-GP阳性表达可作为化疗耐药指标,同时可为化疗方案个体化提供依据。
Objective To investigate the expression of mdr-1 gene product P-glycoprotein in cholangiocarcinoma and its effect on chemotherapy. Methods Immunohistochemical SP method was used to study 35 cases of cholangiocarcinoma and 20 cases of biliary benign lesions with multidrug resistance gene (mdr-) 1) Expression of product P-glycoprotein (P-GP). Results The positive expression of P-GP in 12 cases (34.3%) and biliary benign lesions in 2 cases (10%) were found in 35 cases. The positive expression rate of P-GP in patients undergoing chemotherapy reoperation 83.3% (5/6) was significantly associated with chemotherapy. The expression of P-GP was not associated with pathological type and TNM stage of cholangiocarcinoma. Conclusion The positive expression of P-GP in cholangiocarcinoma can be used as an indicator of chemotherapy resistance, and it can provide the basis for the individualization of chemotherapy regimen.